Who are Begrivac®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): aMIL, MSB0010718C, TAK-019, IMA901, HAPREP®, mRNA-1010.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/begrivac.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Begrivac® — Competitive Intelligence Brief

Begrivac® (Begrivac®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Therapeutic cancer vaccine. Area: Oncology.

phase 3 Therapeutic cancer vaccine Patient-specific tumor neoantigens Oncology Biologic Live · refreshed every 30 min

Target snapshot

Begrivac® (Begrivac®) — Chiltern Pesquisa Clinica Ltda. Begrivac is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Begrivac® TARGET	Begrivac®	Chiltern Pesquisa Clinica Ltda	phase 3	Therapeutic cancer vaccine	Patient-specific tumor neoantigens
aMIL	aMIL	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	marketed	Personalized neoantigen vaccine	Patient-specific tumor neoantigens
MSB0010718C	MSB0010718C	Istituto Oncologico Veneto IRCCS	phase 3	Therapeutic cancer vaccine	Patient-specific tumor neoantigens
TAK-019	TAK-019	Takeda	phase 3	Therapeutic cancer vaccine	Patient-specific tumor neoantigens
IMA901	IMA901	Immatics Biotechnologies GmbH	phase 3	Personalized neoantigen vaccine	Patient-specific tumor neoantigens
HAPREP®	HAPREP®	National Cancer Center, Korea	phase 3	Therapeutic cancer vaccine	Patient-specific tumor neoantigens
mRNA-1010	mRNA-1010	ModernaTX, Inc.	phase 3	Personalized neoantigen vaccine	Patient-specific tumor neoantigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Therapeutic cancer vaccine class)

GlaxoSmithKline · 2 drugs in this class
Green Cross Corporation · 2 drugs in this class
Chiang Mai University · 1 drug in this class
Chiltern Pesquisa Clinica Ltda · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Galena Biopharma, Inc. · 1 drug in this class
Genocea Biosciences, Inc. · 1 drug in this class
ImmunoVaccine Technologies, Inc. (IMV Inc.) · 1 drug in this class
Istituto Oncologico Veneto IRCCS · 1 drug in this class
KU Leuven · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Begrivac® — Competitive Intelligence Brief. https://druglandscape.com/ci/begrivac. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab